<DOC>
	<DOC>NCT00829374</DOC>
	<brief_summary>The purpose of this study is to determine if Dimebon is safe and effective in patients with mild to moderate Alzheimer's disease on Donepezil.</brief_summary>
	<brief_title>Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Mildtomoderate Alzheimer's disease (AD) Probable AD (Diagnostic Statistical Manual of Mental DisordersIVText Revision (DSMIVTR)) MiniMental State Examination (MMSE) score between 12 and 24, inclusive Stable on donepezil for at least 6 months Other causes of dementia Major structural brain disease Unstable medical condition or significant hepatic or renal disease</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Alzheimer's disease</keyword>
	<keyword>clinical trial</keyword>
	<keyword>mitochondria</keyword>
	<keyword>memory loss</keyword>
	<keyword>neurodegenerative disease</keyword>
	<keyword>dementia</keyword>
	<keyword>investigational drug</keyword>
</DOC>